Mind Medicine (MindMed) Inc., doing business as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| MNMD | Mind Medicine (MindMed) Inc. | 2025-10-16 22:04:35 | 11.46 | -0.45 | -3.78 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MNMD | 0001813814 | Mind Medicine (MindMed) Inc. | CA60255C8850 | 549300QY8KN1O6RPFJ13 | — | Nasdaq | 2833 | Medicinal Chemicals & Botanical Products | 1231 | A1 | ONE WORLD TRADE CENTER | NEW YORK | NY | 10007 | UNITED STATES | US | 212-220-6633 | ONE WORLD TRADE CENTER, NEW YORK, NY, 10007 | ONE WORLD TRADE CENTER, NEW YORK, NY, 10007 | — | Biotechnology | 2019 | Robert Barrow | 57 | https://mindmed.co | 515,400,000 | 75,803,251 | 76,087,943 | Mind Medicine (MindMed) Inc., doing business as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs. | 2025-10-10 21:17:36 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 515,400,000 | 375,400,000 | 268.1429 | 75,368,359 | 34,034,052 | 82.3385 |
| 2023 | 140,000,000 | -132,000,000 | -48.5294 | 41,334,307 | 3,270,922 | 8.5934 |
| 2022 | 272,000,000 | -943,700,000 | -77.6261 | 38,063,385 | -383,821,451 | -90.9778 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Schond Greenway | Chief Financial Officer | 2024 | 152,898 | 0 | 0 | 0 | 342,282 | 1,196,149 |
| Robert Barrow | Chief Executive Officer | 2024 | 623,500 | 0 | 0 | 359,216 | 14,294 | 2,669,010 |
| Daniel Karlin | Chief Medical Officer | 2024 | 485,500 | 0 | 0 | 203,424 | 14,395 | 1,330,319 |
| Mark Sullivan | Chief Legal Officer | 2024 | 439,750 | 0 | 0 | 184,288 | 14,569 | 1,161,107 |
| Schond Greenway | Chief Financial Officer | 2023 | 430,000 | 0 | 530,250 | 167,200 | 11,424 | 1,138,869 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 74 |
| 2023 | 57 |
| 2022 | 48 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | — | — | — |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 65,297,000 | 52,124,000 | 36,169,000 |
| General And Administrative Expenses | 38,619,000 | 41,742,000 | 30,162,000 |
| Operating Expenses | 103,916,000 | 93,866,000 | 66,331,000 |
| Operating Income | -103,916,000 | -93,866,000 | -66,331,000 |
| Net Income | -108,679,000 | -95,732,000 | -56,796,000 |
| Earnings Per Share Basic | -1.54 | -2.44 | -1.84 |
| Earnings Per Share Diluted | -1.54 | -2.44 | -1.84 |
| Weighted Average Shares Outstanding Basic | 70,461,067 | 39,157,420 | 30,857,463 |
| Weighted Average Shares Outstanding Diluted | 70,461,067 | 39,157,420 | 30,857,463 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 273,741,000 | 99,704,000 | 142,142,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 281,620,000 | 103,872,000 | 146,055,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | — | — | — |
| Other Assets Non Current | 613,000 | 224,000 | 331,000 |
| Total Assets Non Current | 20,531,000 | 20,669,000 | 23,938,000 |
| Total Assets | 302,151,000 | 124,541,000 | 169,993,000 |
| Accounts Payable | 2,010,000 | 4,136,000 | 2,111,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 12,829,000 | 11,634,000 | 5,877,000 |
| Total Liabilities Current | 38,849,000 | 32,246,000 | 17,892,000 |
| Long Term Debt | 21,854,000 | 14,129,000 | — |
| Other Liabilities Non Current | — | 32,000 | 1,184,000 |
| Total Liabilities Non Current | 21,854,000 | 14,161,000 | 1,184,000 |
| Total Liabilities | 60,703,000 | 46,407,000 | 19,076,000 |
| Common Stock | 0 | — | — |
| Retained Earnings | -398,879,000 | -290,200,000 | -194,468,000 |
| Accumulated Other Comprehensive Income | 819,000 | 343,000 | 627,000 |
| Total Shareholders Equity | 241,448,000 | 78,134,000 | 150,917,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | — | — | — |
| Share Based Compensation Expense | — | — | — |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -2,126,000 | 2,025,000 | -2,056,000 |
| Change In Other Liabilities | 3,103,000 | 5,318,000 | -416,000 |
| Cash From Operating Activities | -79,129,000 | -64,365,000 | -50,139,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | — | — | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -30,000 | 79,000 | -309,000 |
| Tax Withholding For Share Based Compensation | 54,000 | — | 407,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 984,000 | 7,529,000 | 42,297,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 10,000,000 | 15,000,000 | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 253,196,000 | 21,848,000 | 59,051,000 |
| Change In Cash | 174,037,000 | -42,438,000 | 8,603,000 |
| Cash At End Of Period | 273,741,000 | 99,704,000 | 142,142,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 2,224,000 | 534,000 | 1,495,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -1.54 | -2.44 | -1.84 |
| Price To Earnings Ratio | -4.5195 | -1.5 | -1.1957 |
| Earnings Growth Rate | -36.8852 | 32.6087 | — |
| Price Earnings To Growth Ratio | 0.1225 | -0.046 | — |
| Book Value Per Share | 3.4267 | 1.9954 | 4.8908 |
| Price To Book Ratio | 2.0311 | 1.8342 | 0.4498 |
| Ebitda | — | — | — |
| Enterprise Value | 238,522,026.32 | 57,741,157.2 | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.0905 | 0.1808 | — |
| Capital Expenditures | — | — | — |
| Free Cash Flow | — | — | — |
| Return On Equity | -0.4501 | -1.2252 | -0.3763 |
| One Year Beta | 1.9467 | 2.0597 | 1.3312 |
| Three Year Beta | 1.5862 | 1.7277 | 1.4722 |
| Five Year Beta | 1.5519 | 1.5199 | 1.4722 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Karlin Daniel | Chief Medical Officer | 2025-09-25 | 7,704 | D | 430,625 |
| Barrow Robert | Director, Chief Executive Officer | 2025-09-25 | 25,797 | D | 804,268 |
| Sullivan Mark | Chief Legal Officer | 2025-09-25 | 11,278 | D | 293,852 |
| Barrow Robert | Director, Chief Executive Officer | 2025-06-25 | 26,491 | D | 830,065 |
| Karlin Daniel | Chief Medical Officer | 2025-06-25 | 7,848 | D | 438,329 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| NVWM, LLC | 2025-09-30 | 4,905 | 416 | 11.7909 |
| CWM, LLC | 2025-09-30 | 53,000 | 4,532 | 11.6946 |
| Robbins Farley | 2025-09-30 | 331 | 28 | 11.8214 |
| Farther Finance Advisors, LLC | 2025-09-30 | 5,388 | 457 | 11.7899 |
| Sound Income Strategies, LLC | 2025-09-30 | 46,013 | 3,681 | 12.5001 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 314 | 2,854.26 | 0.0012 |
| Global X Funds | 2025-07-31 | Global X Russell 2000 ETF | RSSL | 38,356 | 348,656.04 | 0.0265 |
| FIDELITY CONCORD STREET TRUST | 2025-07-31 | Fidelity ZERO Total Market Index Fund | FZROX | 33,158 | 301,406.22 | 0.0011 |
| FIDELITY CONCORD STREET TRUST | 2025-07-31 | Fidelity ZERO Extended Market Index Fund | FZIPX | 20,608 | 187,326.72 | 0.0102 |
| ProFunds | 2025-07-31 | SMALL-CAP PROFUND SERVICE CLASS | SLPSX | 68 | 618.12 | 0.0178 |